Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Thyrocare TechnologiesNSE:THYROCARE +3.48%87 Days Inventory is 71.14 as of Jun. 2026, which is 20% above its 10-year median of 59.34. GuruFocus rates NSE:THYROCARE with a GF Score™ of 87/100 and a GF Value™ of ₹411.55 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 179 Medical Diagnostics & Research companies, Thyrocare Technologies ranks worse than 53.07% on this metric.
The historical rank and industry rank for Thyrocare Technologies's Days Inventory or its related term are showing as below:
NSE:THYROCARE'
s Days Inventory Range Over the Past 10 Years
Min: 48.97 Med: 59.34 Max: 89.8
Current: 73.65
During the past 13 years, Thyrocare Technologies's highest Days Inventory was 89.80. The lowest was 48.97. And the median was 59.34.
NSE:THYROCARE's Days Inventory is ranked worse than 53.07% of 179
companies
in the Medical Diagnostics & Research industry
Industry Median: 65.04
vs NSE:THYROCARE: 73.65
Thyrocare Technologies's Days Inventory
declined
from Jun. 2025 (76.34) to Jun. 2026 (71.14).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Thyrocare Technologies's Inventory Turnover for the
three
months ended in Jun. 2026 was 1.28.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Thyrocare Technologies's Inventory-to-Revenue for the
three
months ended in Jun. 2026 was 0.20.
Thyrocare Technologies (NSE:THYROCARE) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Thyrocare Technologies's Inventory Turnover for the
three
months ended in Jun. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Thyrocare Technologies's Inventory to Revenue for the
three
months ended in Jun. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Thyrocare Technologies Days Inventory Related Terms
Thyrocare Technologies Days Inventory Historical Data
* Premium members only.
The historical data trend for Thyrocare Technologies's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:THYROCARE vs TMO, DHR, IDXX: Days Inventory Comparison
For the Diagnostics & Research subindustry, Thyrocare Technologies's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Thyrocare Technologies Days Inventory vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Thyrocare Technologies's Days Inventory distribution charts can be found below:
* The bar in red indicates where Thyrocare Technologies's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thyrocare Technologies (NSE:THYROCARE) has a Days Inventory of 71.14 as of Jun. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Thyrocare Technologies and its competitors. This is 20% above median its historical median of 59.34. Over the past decade, Thyrocare Technologies' Days Inventory has ranged from 48.97 to 89.80. According to the industry distribution chart, Thyrocare Technologies ranks #95 out of 179 companies in the Medical Diagnostics & Research industry, placing it in the top 53.1%.
Is Thyrocare Technologies' Days Inventory too high?
Thyrocare Technologies' current Days Inventory of 71.14 is 20% above median its 10-year median of 59.34. Over the past 10 years, this metric has ranged from a low of 48.97 to a high of 89.80. The Medical Diagnostics & Research industry median Days Inventory is 65.04. Thyrocare Technologies' value of 71.14 is 9.4% above this industry median. Based on the distribution chart, Thyrocare Technologies ranks #95 out of 179 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Thyrocare Technologies has a GF Score™ of 87/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Thyrocare Technologies' Days Inventory compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Thyrocare Technologies ranks #95 out of 179 companies for Days Inventory. This places Thyrocare Technologies in the lower half of its industry. The industry median Days Inventory is 65.04. Thyrocare Technologies' value of 71.14 is 9.4% above this benchmark. Historically, Thyrocare Technologies' own Days Inventory has ranged from 48.97 to 89.80 over the past decade. While the company's 10-year median is 59.34 vs. the industry median of 65.04, Thyrocare Technologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Medical Diagnostics & Research company?
The median Days Inventory among Medical Diagnostics & Research companies is 65.04, based on 179 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Thyrocare Technologies's current Days Inventory of 71.14 is 9.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Thyrocare Technologies and its competitors. For the Medical Diagnostics & Research industry, the median Days Inventory is 65.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Thyrocare Technologies's current Days Inventory is 71.14, which is 20% above median its own 10-year median of 59.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Thyrocare Technologies stock overvalued right now?
Based on GuruFocus' analysis, Thyrocare Technologies (NSE:THYROCARE) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹411.55, compared to a current price of ₹564.25 — trading 37.1% above its estimated fair value. The current Days Inventory is 71.14, which is 20% above median its 10-year median of 59.34 and 9.4% above the Medical Diagnostics & Research industry median of 65.04. Thyrocare Technologies' overall GF Score™ is 87/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Thyrocare Technologies (NSE:THYROCARE), the current Days Inventory is 71.14 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Thyrocare Technologies (NSE:THYROCARE) Overvalued in 2026?
Based on GuruFocus' analysis, Thyrocare Technologies stock appears to be overvalued.
The current stock price of ₹564.25 is trading 37.1% above its estimated GF Value™ of ₹411.55.
GuruFocus considers Thyrocare Technologies to be Significantly Overvalued.
Key valuation signals for NSE:THYROCARE:
Days Inventory: 71.14 (20% above median its 10-year median of 59.34)
GF Value™: ₹411.55 vs. price of ₹564.25 (37.1% above fair value)
Industry Position: 9.4% above the Medical Diagnostics & Research median (#95 of 179)
No single metric tells the full story. See the NSE:THYROCARE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Thyrocare Technologies Ltd is a diagnostics & research company. The company has three business segments: Diagnostic Testing Services, Imaging Services, and Others: Sale of testing equipment and consumables. The Diagnostic Testing Services segment provides Diagnostic and testing services, selling of consumables used for the collection and promotion of the pathology segment. The company majorly earns the majority of its revenue from the Diagnostic Testing Services segment. The Imaging Services segment operates Diagnostic and imaging services, selling of radio-pharmaceuticals, and selling of consumables for reporting. The Other business segment is engaged in the selling of glucometers and glucostrips under the brand name Sugarscan. The company earns the vast majority of its revenue in India.
87GF Score
Get the complete analysis for NSE:THYROCARE
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:THYROCARE has been successfully added to your 
